TD Cowen analyst Ritu Baral maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $98.00. The ...

RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Wednesday the submission of its supplemental New Drug ...

Shares of Soleno Therapeutics SLNO jumped 9.1% on Tuesday and continued to gain another 4.1% during the after-market hours ...

The FDA in 2022 approved Amvuttra to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, a rare debilitating disease that damages nerves, and analysts have predicted ...

Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines ...

Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...